A New Series of Pyridinone Derivatives as Potent Non-Nucleoside Human **Immunodeficiency Virus Type 1 Specific Reverse Transcriptase Inhibitors**

Valérie Dollé,[†] E Fan,[†] Chi Hung Nguyen,[†] Anne-Marie Aubertin,[‡] André Kirn,[‡] Marie Line Andreola,[§] Gordon Jamieson,[§] Laura Tarrago-Litvak,[§] and Emile Bisagni^{*,†}

URA 1387 CNRS, Synthèse Organique, Institut Curie, Section de Recherche, Bâtiment 110, 15 rue Georges Clémenceau, 91405 Orsay, France, INSERM U74, Institut de Virologie, 3 rue Koeberlé, 67000 Strasbourg, France, and UPR 9026 CNRS, Laboratoire de Réplication et Expression des Génomes Eucaryotes et Rétroviraux, Institut de Biochimie et Génétique Cellulaires, 1 rue Camille-St-Saëns, 33077 Bordeaux cedex, France

Received June 2, 1995[®]

4-(Arylthio)-pyridin-2(1H)-ones variously substituted in their 3-, 5-, and 6-positions have been synthesized as a new series of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)pyridinone hybrid molecules. Biological studies revealed that some of them show potent HIV-1 specific reverse transcriptase inhibitory properties. Compounds 16 and 7c, the most active ones, inhibit the replication of HIV-1 at 3 and 6 nM, respectively.

Introduction

Among HIV-1 specific reverse transcriptase (RT) inhibitors, HEPT derivatives 1a,b and pyridinones 2a,b are interesting leads which emerged from various structure-activity relationship (SAR) studies in these series¹⁻⁸ (Figure 1).

Our continuing interest for the search of new anti-HIV drugs led us to design pyridinones 3 as potential specific human immunodeficiency virus type 1 (HIV-1) RT inhibitors. Indeed, the way considered toward these 1-2 hybrid molecules, which are new pyridinone derivatives, allowed us to conceive to obtain easily a large panel of 3-6-substituted compounds and therefore to study thoroughly the SAR in this series.

We report in this paper the synthesis and biological properties of this new series of 1-2b-related compounds 3.

Chemistry

Starting from 4-hydroxy-5-methyl-pyridin-2(1H)-one (4a)⁹ the nitro derivative **5a** and the chloronitropyridinone **6a** were prepared as previously described.¹⁰ Condensation with 3.5-dimethylthiophenol led to 4-[(3',5'dimethylphenyl)thio]-5-methyl-3-nitropyridin-2(1H)one (7a) in 92% yield, and reduction with stannous chloride dihydrate in boiling ethyl acetate gave 87% of the amine 8a (Scheme 1). In the same manner and in order to study the SAR in this new 5-methylpyridin-2(1H)-one series, variously 3- and 4-substituted derivatives have been synthetized. Compounds 7d,e and 8e were obtained by condensation of the chloronitropyridinone 6a with thiophenol or *m*-thiocresol followed by the reduction of the nitro function (in the case of **8e**). According to Scheme 2, compounds 10a-h were obtained from 2-mercapto derivatives of pyrimidines, benzimidazole, benzoxazole, benzothiazole, thiazoline, imidazole, and pyridine with a yield ranging from 10% to 98%. The 4-anilinopyridinone derivative 9 was also prepared in the standard method using 3,5-dimethylaniline instead of the mercapto reagent, and aminopyridinone 11 was obtained by reduction of 10d, in the usual conditions.


Upon the model of the 3-amino-substituted pyridinone 2b, modifications of the amino function of 3-amino-5methyl-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)one (8a) and 3-amino-5-ethyl-6-methyl-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one (8c) newly synthesized have been performed. Thus, in the usual amidification conditions, using ethyl formate, acetic anhydride, propionyl chloride, heptanoic anhydride, and phenylacetyl chloride, the amides 12a-e,g were obtained in 50-90%yields (Scheme 3). The 3-(N-ethoxycarbamoyl) derivative 12f was also synthesized in the same conditions with ethyl chloroformate in 26% yield.

It is worth mentioning that in various conditions no condensation occurred from this 3-aminopyridinone 8a and 4,5-dimethyl-2-methoxybenzaldehyde, contrary to that described by Wai et al. in the case of the 3-amino-5-ethyl-6-methylpyridin-2(1H)-one.⁶ This failure could be explained by the steric hindrance of the neighboring thiophenyl group and the basicity of this 3-amino group which seems to be weak since its methylation in the Eschweiler-Clark reaction^{11,12} using formic acid and formaldehyde in various conditions was unsuccessfull.

At this stage, all new 3- and 4-substituted 5-methylpyridin-2(1H)-one derivatives were submitted to biological evaluation. Results were interesting and revealed that the most active compounds fitted a nitro or amino function and a (3,5-dimethylphenyl)thio group at their 3- and 4-positions, respectively. These characteristic structural requirements were then extended to the 5-ethyl- and 5-ethyl-6-methylpyridinone analogues, starting either from the known 5-ethyl-4-hydroxypyridin-2(1H)-one $(4b)^{13}$ or from 5-ethyl-4-hydroxy-6-methylpyridin-2(1H)-one (4c) which was prepared in a two-step sequence from ethyl 2-ethylaminocrotonate 13 and diethyl malonate (Scheme 4). Then, nitration, monochlorination, substitution with 3,5-dimethylthiophenol, and reduction of the nitro function occurred smoothly (Scheme 1) leading to the 3-nitro- and 3-aminopyridinone derivatives 7b, 8b and 7c, 8c, respectively. The 5,6-benzopyridinone analogues, 7f and 8f were also obtained in the

[†] URA 1387 CNRS. [‡] INSERM U74. [§] UPR 9026 CNRS.


[®] Abstract published in Advance ACS Abstracts, October 15, 1995.



 a Reagents: (a) HNO_3/Δ ; (b) $POCl_3/benzyltriethylammonium chloride/CH_3CN/\Delta_{reflux}$; (c) thiophenol/Et_3N/EtOH/room temperature; (d) $SnCl_2\cdot 2H_2O/EtOAc/\Delta_{reflux}$; (e) 3,5-dimethylaniline/Et_3N/EtOH/ Δ_{reflux} .

same way using the commercially available quinoline-2,4-diol (4f) as starting material.

Finally, the intermediate 3-carbethoxy-4-hydroxypyridinone 14, obtained as an intermediate during the preparation of the 5-ethyl-6-methylpyridinone 4c, was successively transformed into 4-chloropyridinone 15 and 4-(phenylthio)pyridinone 16 in the standard conditions. Attempts to perform hydrolysis of the 3-carbethoxypyridinone 16 were however followed by the unavoidable decarboxylation, leading to the 3-unsubstituted pyridinone 17 in acidic conditions or to the partial degradation of the starting material in ethanol with 5% sodium hydroxide.



СН,


12 (12g)

 CH_2CH_3 , $R_3 = CH_3$, acetic anhydride/acetic acid/ $\Delta_{reflux}/5.5$ h.

Biological Results

Inhibition of HIV-1 Multiplication. Thirty newly synthesized pyridinones were studied for their anti-HIV-1 biological activity. Several molecules showed significant antiviral properties. For example, the most

Scheme 4^a



^a Reagents: (a) (1) diethyl malonate/EtONa/EtOH/ Δ_{reflux} , (2) 13/ Δ_{reflux} ; (b) POCl₃/benzyltriethylammonium chloride/CH₃CN/ Δ_{reflux} ; (c) 3,5-dimethylthiophenol/Et₃N/EtOH/ Δ_{reflux} ; (d) THF/H₂O/HCl (37%) (18:3:4)/75 °C; (e) HCl(1 N)/ Δ_{reflux} .

Table 1.	Anti-HIV-1	Biological	Activity	of the	Pyridinones or	1
$HIV-1_{IIIB}$	Wild Type					

compd	$IC_{50}(nM)$	$CC_{50}(nM)$	SI
AZT	3	>100 000	>33333
7a	120	>10 000	>83
7b	≈ 90	>10 000	>111
7c	≈6	>10 000	>1666
7d	>10 000	>10 000	
7e	2800	>10 000	>3
7f	3800	>100 000	>26
8a	10	>10 000	>1000
8b	10	>10 000	>1000
8c	14	>10 000	>714
8e	1400	$78\ 000$	>55
8f	250	>9000	>36
9	$45\ 000$	>100 000	>2
1 0a	$17\ 500$	19 500	>1
10 b	>100 000	>100 000	
1 0c	$43\ 500$	54 500	>1
1 0d	5500	16 000	>2
1 0e	$14\ 500$	$13\ 500$	
1 0f	17 000	$21\ 500$	>1
1 0g	56 000	68 500	>1
1 0h	18 000	$28\ 500$	>1
11	8000	7500	
1 2a	6600	>100 000	>15
1 2b	67	>100 000	>1492
1 2c	41 400	>100 000	>2
12d	>10 000	>10 000	
1 2e	>10 000	>10 000	
1 2f	7500	>100 000	>13
1 2g	50	80 000	1600
1 6	3	>10 000	>3333
17	500	>10 000	>20

actives ones are the compounds 16 and 7c with IC_{50} s of 3 and 6 nM, respectively (see Table 1). The best inhibitors, namely, those which display a selective index (SI) superior to 20, were tested on a Nevirapine resistant strain (see Table 2). It was found that compound 7c has good anti-HIV-1 activity with an IC_{50} of 260 nM on this resistant strain.

Inhibition of RT. Compounds found active against HIV-1 in cell culture were tested on recombinant HIV-1 RT. The concentration inhibiting 50% of the RT activity (IC₅₀) for each compound is given in Table 3. Compounds 7c and 8c were the best inhibitors with IC₅₀ values of 30 and 15 nM, respectively. A HEPT derivative, 1-[(benzyloxy)methyl]-6-(phenylthio)thymine or

 Table 2. Anti-HIV-1 Activity of the Pyridinones on HIV-1

 Nevirapine Resistant Strain

compd	$IC_{50}\left(nM ight)$	$CC_{50}\left(nM ight)$	SI	
TIBO R82913	>10 000	>10 000		
7a	>10 000	>10 000		
7b	6700	>10 000	>1	
7c	260	>10 000	>38	
7f	>10 000	>10 000		
8a	>10 000	>10 000		
8b	6700	>10 000	>1	
8c	2100	>10 000	>4	
8e	$41\ 500$	78 000	>1	
8f	6600	8200	>1.5	
1 2b	>100 000	>100 000		
1 2g	4300	>100 000	>23	
16	2200	>10 000	>4.5	

Table 3. Inhibition of HIV-1 Reverse Transcriptase (RT)^a

compd	$IC_{50}\left(nM ight)$	compd	IC ₅₀ (nM)
HEPT	> 6000	8c	15
BPT	400	8e	>4000
7a	>10 000	12b	>4000
7c	30	12c	>4000
7e	>10 000	1 6	600
8a	100	17	400

 a RT activity was measured in the presence of poly(C)-oligo(dG), as described in the Experimental Section.

BPT, 14 tested in the same conditions and used as a reference of non-nucleoside inhibitor gave an IC_{50} value of 400 nM.

As all the derivatives were synthesized to obtain inhibitors targeted toward RT, it was important to perform studies allowing an insight on the nature of the inhibition. These studies were done mainly with 7c and 8c.

The inhibition of RT was determined using different template-primers. It has been previously described that non-nucleoside RT inhibitors show different levels on inhibition depending on the template-primer used to measure the RT activity.¹⁵ Dose—response curves for **7c** in the presence of two different template-primers are shown in Figure 2. Better inhibition was obtained in the presence of poly(C)-oligo(dG) as compared to that obtained with poly(A)-oligo(dT). Compound **8c** gave the same result (not shown). With HIV-1 RNA used as natural template, a strong inhibition was also obtained




Figure 2. Effect of compound 7c on HIV-1 and HIV-2 RT.




Figure 3. Inhibition of reverse transcription by compound 7c. Reverse transcription was performed as described in the Experimental Section. The expected cDNA product (147 nucleotides long) is indicated in the left of the panel. Lane 1: control in the presence of the whole system. Lanes 2-5: same as lane 1 but in the presence of different concentrations of compound 7c. Lane 2: 400 nM 7c. Lane 3: 300 nM 7c. Lane 4: 100 nM 7c. Lane 5: 40 nM 7c.

(Figure 3). The pyridinone derivatives show marked template-primer preferences, poly(C)-oligo(dG) being the most efficient. With poly(C)-oligo(dG), the IC₅₀s of **7c** and **8c** were respectively 7- and 13-fold lower than with poly(A)-oligo(dT).

All non-nucleoside inhibitors so far identified are specific for HIV-1 and do not inhibit RT from HIV-2. Compounds **7c** and **8c** were tested with both RTs. As shown in Figure 2, at concentrations where HIV-1 RT was well inhibited, the activity of HIV-2 RT was not affected. This discriminatory behavior toward HIV-1 vs HIV-2 RT makes these compounds share another common property of non-nucleoside inhibitors.

Enzyme kinetic analyses show that the inhibition of HIV-1 RT by compound **7c** (or **8c**) was noncompetitive with respect to the substrate dGTP in the presence of the template-primer poly(C)-oligo(dG) (Figure 4). When poly(A)-oligo(dT) was used as template-primer, a competitive type of inhibition was obtained (Figure 5). The competitive type of inhibition has also been shown for other non-nucleoside inhibitors. It is the case, for example, of a HEPT derivative (E-EPU) that competitively inhibits the HIV-1 RT reaction (with respect to dTTP) if the reaction is directed by poly(A)-oligo(dT).¹⁴ These data point to the possibility of the existence of two functionally (and possibly also spatially) related RT-binding sites differing in their affinity to the deriva-




Figure 4. Double-reciprocal (Lineweaver-Burk) plot for inhibition of HIV-1 RT by compound **7c** with poly(C)-oligo-(dG) as the template-primer and dGTP as substrate.




Figure 5. Double-reciprocal (Lineweaver-Burk) plot for inhibition of HIV-1 RT by compound **7c** with poly(A)-oligo-(dT) as the template-primer and dTTP as substrate.

tives: a first binding site, different from the substratebinding site, that leads to a noncompetitive type of inhibition and a second binding site that causes a competitive type of inhibition.¹⁴

Discussion

In this work, studies were first realized on a variety of 3- and 4-substituted 5-methylpyridin-2(1H)-one derivatives in order to define the characteristic structural requirements for biological activities. The results arising from these studies were then extended to the 5-ethyland 5-ethyl-6-methylpyridinones, and to the quinolin-2(1H)-one analogues as well.

Thus, from these initial SAR studies of 20 new derivatives belonging to the 5-methylpyridin-2(1H)-one series, some general comments can be drawn (see Table 1). (a) Like in the HEPT series, 16,17 the two methyl groups at the 3- and 5-positions of the thiophenyl substituent play an important role for biological activity. Thus, in our tests, 4-(thiophenyl)pyridinone 7d was inactive, the 3-methylphenyl analogue 7e displayed moderate activity (IC₅₀ = 2800 nM) similar to that of the HEPT derivative 1a (IC₅₀ = 6000 nM), but the 3,5dimethylphenyl derivative 7a exhibited a more pronounced inhibitory effect (IC₅₀ = 120 nM). (b) When the sulfur atom in the thioether function was replaced by an NH group as in the case of the compound 9, with respect to its analogue 7a, RT inhibitory properties were totally abolished. (c) If various heterocycles took place at the 4-position of the 5-methylpyridinones, the same results were observed (compounds 10a-h and 11) (Scheme 2). Contrary to results described by Pan et al.¹⁸ for 2-pyridylthio HEPT derivatives, this group is inadequate for our pyridinone analogues (compare 10h vs 7a). (d) A striking decrease or an abolishment of biological activity was also observed for amides and carbamates derived from amino derivative 8a, with IC₅₀s which reach values 1000-fold higher than that of their amino counterparts (compare 8a vs 12a,c-f).

New Pyridinone Derivatives as RT Inhibitors

3-Acetamidopyridinone derivative 12b was yet a particular exception to these findings. Indeed, this compound displayed an IC_{50} value equal to 67 nM, which is only 6-fold higher than that of amine 8a (10 nM). Since the cytotoxicity of 12b was significantly lower (*ca.* 10-fold), its selectivity index was better.

For 5-methylpyridinone derivatives, it was obvious that the characteristic structural requirements to display significant biological activity are the presence of a (3,5-dimethylphenyl)thio group at their 4-position together with a 3-nitro or, at the best, a 3-amino function (compare 7a vs 8a, 7b vs 8b, 7e vs 8e, and 7f vs 8f).

The substituents present at the 5- and 6-positions also play a very important role in this series. Thus, quinolone derivatives corresponding to compounds with a fuzed benzo ring at these positions resulted in the weak inhibitors **7f** and **8f**. On the contrary, a 5-ethyl group (**7b** and **8b**) and 5-ethyl plus 6-methyl substituents (**7c** and **8c**), led to highly active compounds, with IC₅₀ values ranging from 90 (**7b**), 14 (**8c**), 10 (**8b**), and 6 (**7c**) nM.

Finally, a complementary result which clearly showed the importance of the 3-substituent group in this series was given by the comparison of biological activities of 5-ethyl-6-methyl-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one (17) (IC₅₀ = 500 nM) to those of its 3-carbethoxy analogue 16 (IC₅₀ = 3.1 nM) which is the most efficient compound in this series, at least up to date, but less active on RT. To explain this difference, one may hypothesize that compound 16 may act as a prodrug which can be activated in the culture medium or the cell, activation which would not occur during the RT assay (see Table 3). Another possibility is that the molecule 16 may have, in addition to RT, other viral targets during the replication cycle, and the effects could be additive or synergistic.

Conclusion

This work led us to obtain a new series of potent nonnucleoside HIV-1 RT inhibitors. They are 4-(arylthio)-3,5,6-trisubstitutedpyridin-2(1H)-one derivatives related to both HEPT and the Merck pyridinone series. Though totally novel, they can be considered as a hybrid of these two lead models. The worked out pathway to these molecules will probably allow us to obtain a large panel of analogues and related compounds which could be useful for a more elaborate SAR study.

From the biological point of view, biochemical studies showed that compounds 7c and 8c strongly inhibited the activity of a recombinant HIV-1 RT. The derivatives showed different levels of inhibition depending on the template-primer used. Better levels of inhibition were obtained with a template-primer of poly(C)-oligo(dG), as compared to poly(A)-oligo(dT). Enzyme kinetic analysis of RT inhibition by these compounds indicated that they were noncompetitive with respect to the substrate dGTP. Compounds 7c and 8c did not inhibited HIV-2 RT. All these properties enable us to classify compounds 7c and 8c as HIV-1 specific non-nucleoside RT inhibitors.

Besides trying to use our findings to develop new and more efficient HIV-RT inhibitors, our results could also serve for a better understanding of the main parameters involved in the interactions of these compounds with the "allosteric" site of RT.

Journal of Medicinal Chemistry, 1995, Vol. 38, No. 23 4683

Table 4.4-Hydroxy-3-nitropyridin-2(1H)-ones**5b,c** and4-Hydroxy-3-nitroquinolin-2(1H)-one(**5f**): Physical Data

no.	yield (%)	mp (°C)	formula	anal.
5b	82	213–214 (water) ^a	$\begin{array}{c} C_7H_8N_2O_4{\cdot}0.25H_2O\\ C_8H_{10}N_2O_4\\ C_9H_6N_2O_4 \end{array}$	C, H, N
5c	85	255–256 (water) ^a		C, H, N
5f	98	250 (none) ^a		C, H, N

^a Recrystallization solvent.

Table 5.4-Chloro-3-nitropyridin-2(1H)-ones6b,c,4-Chloro-3-nitroquinolin-2(1H)-one(6f), and4-Chloro-5-ethyl-6-methyl-3-carbethoxypyridin-2(1H)-one(15):Experimental Conditions and Physical Data

no.	POCl ₃ ^a (mol equiv)			mp (°C)	formula	anal.
6b	4.4	1	74	с	с	с
6c	4.4	1	34	с	с	с
6f	2.4	0.3	67	с	с	с
1 5	4.4	6	71	167^d	$\mathrm{C_{11}H_{14}NO_{3}Cl}$	C, H, N, Cl

^a Optimized proportion. ^b Rfx = heating (reflux) times in hours (h). ^c See caution in the Experimental Section. ^d The crude product was crystallized in ethyl acetate to give white crystals.

Experimental Section

Chemistry. TLC was carried out on precoated plates of silica gel 60F254 (Merck). In order to reveal the compounds, TLC plates were exposed to UV light. Purifications were performed on silica gel (40–60 μ m, SDS) columns by medium pressure chromatography. All melting points were measured on an Electrothermal 9200 apparatus and are uncorrected. ¹H NMR spectra were recorded in the given solvents with a Bruker AC 200 apparatus with CHCl₃ (δ = 7.25 ppm) or DMSO (δ = 2.54 ppm) as internal standard (* and # = interchangeable assignments). Elemental analyses, performed by the Service Central de Microanalyses du CNRS, 91190 Gifsur-Yvette, France, were within 0.3% of the theoretical values calculated for C, H, N, S, and Cl.

CAUTION: Because of the strong allergic effects on the skin of the chloronitropyridinone derivatives 6b, c, f, their manipulation should be carried out in a ventilated hood and the use of gloves is recommended. This is the reason why they were used without further purification and the elemental analyses and the meltings points were not performed for these compounds.

5-Ethyl-4-hydroxy-6-methylpyridin-2(1*H*)-one (4c). The ester 14 prepared as described below (17.2 g, 76.4 mmol) was dissolved in 1.2 L of an aqueous solution of HCl (1 N), and the mixture was heated under reflux for 36 h. After evaporation of the solvent, 100 mL of water was added, and the mixture was neutralized with aqueous ammonia. The precipitate was filtered off and washed with water. The product 4c was obtained (11.2 g, 96%) as a white solid: mp 360 °C; ¹H NMR (DMSO- d_6) δ 10.75 (1H, s, NH-1), 5.46 (1H, s, H-3), 2.32 (2H, q, J = 7 Hz, CH_2CH_3), 2.13 (3H, s, CH_3 -6), 0.99 (3H, t, J = 7 Hz, CH_2CH_3). Anal. (C₈H₁₁NO₂) C, H, N.

4-Hydroxy-3-nitropyridin-2(1*H*)-ones 5b,c and 4-Hydroxy-3-nitroquinolin-2(1*H*)-one (5f) (Table 4). Preparation of 5-Ethyl-4-hydroxy-3-nitropyridin-2(1*H*)-one (5b): Example of the General Method. A suspension of 4b¹³ (5.00 g, 36.0 mmol) in 40 mL of nitric acid (d = 1.33) was stirred for 10 min at room temperature and at 75 °C during 12 min; 150 mL of ice water was added immediately, and the yellow precipitate was filtered off and recrystallized from water giving the nitropyridinone 5b (5.4 g, 82%) as yellow crystals: mp 213-214 °C; ¹H NMR (DMSO- d_0) δ 11.85 (1H, s, NH-1), 7.39 (1H, s, H-6), 2.42 (2H, q, J = 7 Hz, CH₂), 1.10 (3H, t, J = 7 Hz, CH₃). Anal. (C₇H₈N₂O₄·0.25H₂O) C, H, N.

Chlorination Reaction for the Production of the 4-Chloro-3-nitropyridin-2(1*H*)-ones 6b,c, 4-Chloro-3-nitroquinolin-2(1*H*)-one (6f), and 4-Chloro-5-ethyl-6-methyl-3-carbethoxypyridin-2(1*H*)-one (15) (Table 5). Preparation of 4-Chloro-5-ethyl-3-nitropyridin-2(1*H*)-one (6b): Example of the General Method. To a solution of 5b (3.00 g, 16.3 mmol) and benzyltriethylammonium chloride (14.90 g, 65.2 mmol) in acetonitrile (60 mL) was added phosphorus oxychloride (6.7 mL, 71.9 mmol). The obtained mixture was

Table 6. 3-Nitro-4-(phenylthio)pyridin-2(1H)-ones7a-f, 3-Nitro-5-methyl-4-[(3',5'-dimethylphenyl)amino]pyridin-2(1H)-one (9),3-Nitro-4-(arylthio)-pyridin-2(1H)-ones10a-h, and 5-Ethyl-6-methyl-3-carbethoxy-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one(16):Experimental Conditions and Physical Data

no.	$T(^{\circ}C)$ (time, h)	yield (%)	purification technique ^a	mp (°C)	formula	anal.
7a	20 (1)	92	cyclohexane*	235	$C_{14}H_{14}N_2O_3S \cdot 0.25H_2O$	C, H, N, S
7b	20 (4)	53	ethanol#	197	$C_{15}H_{16}N_2O_3S$	C, H, N, S
7c	20 (3)	81	ethanol#	236 - 237	$C_{16}H_{18}N_2O_3S$	C, H, N, S
7d	20 (15)	47	ethanol#	214 - 216	$C_{12}H_{10}N_2O_3S \cdot 0.10H_2O$	C, H, N, S
7e	$20(15)^{b}$	71	water*, ethanol#	222 - 223	$C_{13}H_{12}N_2O_3S \cdot 0.25H_2O$	C, H, N, S
7f	50 (2.5) ^b	59	water/hexane*	294	$C_{17}H_{14}N_2O_3S$	C, H, N, S
			ethanol#			, , , ,
9	reflux (1)	79	ethanol#	273 - 275	$C_{14}H_{15}N_{3}O_{3}$	C, H, N
1 0a	reflux $(3)^b$	58	water*	238 - 239	$C_{12}H_{12}N_4O_3S \cdot 0.125H_2O$	C, H, N, S
1 0b	reflux (4.5)	30	water*	>350	$C_{11}H_{10}N_4O_4S$	C, H, N, S
			chromatography ^c			
10c	reflux $(6.5)^b$	66	water*	272 - 275	$C_{13}H_{10}N_4O_3S_{1}O_25H_2O_25C_2H_5OH$	C, H, N
10 d	reflux (3)	27	ethanol#	180 - 181	$C_{13}H_9N_3O_4S \cdot 0.5C_2H_5OH$	C, H, N, S
1 0e	reflux (4)	60	water*	240	$C_{13}H_9N_3O_3S_2$	C, H, N
1 0f	reflux (8) ^b	7	water*	177	$C_{9}H_{9}N_{3}O_{3}S_{2} \cdot 0.25C_{2}H_{5}OH$	C, H, N
			$chromatography^d$			
10g	reflux $(6)^b$	85	water*	260 - 265	$C_{10}H_{10}N_4O_3S$	C, H, N, S
10 h	20 (48)	66	water*	195 - 196	$C_{11}H_9N_3O_3S$	C, H, N, S
1 6	reflux (12)	82	ethyl acetate [#]	202	$C_{19}H_{23}NO_3S$	C, H, N, S

^a Asterisk = washing and pound sign = recrystallization. ^b The mixture was evaporated to dryness before the treatment. ^c After extraction with ethyl acetate, the crude mixture was chromatographed on a silica gel column using hexane-ethyl acetate (1:1-0:1) and ethyl acetate-ethanol (95:5-9:1) as eluants. ^d Flash chromatography on a silica gel column using dichloromethane-ethanol (1:0-9:1) as eluant.

 Table 7.
 3-Amino-4-(phenylthio)pyridin-2(1H)-ones
 8a-c,e,f
 and
 3-Amino-5-methyl-4-(benzoxazol-2-ylthio)pyridin-2(1H)-one
 (11):

 Experimental Conditions and Physical Data
 Data
 3-Amino-5-methyl-4-(benzoxazol-2-ylthio)pyridin-2(1H)-one
 (11):

no.	T (°C) (time, h)	yield (%)	purification technique	mp(°C)	formula	anal.
8a	reflux (1)	87	chromatography ^a	208	C ₁₄ H ₁₆ N ₂ OS	C, H, N, S
8b	70 (1)	64	chromatography ^a	208 - 209	$C_{15}H_{18}N_2OS \cdot 0.25H_2O$	C, H, N, S
8c	70(1)	88	chromatography ^b	188 - 189	$C_{16}H_{20}N_2OS$	C, H, N, S
8e	80 (20)	56	chromatography ^c	170 - 171	$C_{13}H_{14}N_2O_3S$	C, H, N, S
8f	70 (1)	52	recrystallization in ethyl acetate	235 - 236	$C_{17}H_{16}N_2OS \cdot 0.25H_2O$	C, H, N, S
11	reflux (6)	10	dichloromethane washings	296 - 297	$\mathrm{C_{13}H_{11}N_{3}O_{2}S\cdot H_{2}O}$	C, H, N

^a Flash chromatography on a silica gel column using dichloromethane-ethanol (9:1) as eluant. ^b Flash chromatography on a silica gel column using dichloromethane-ethanol (95:5-9:1) and ethyl acetate as eluants. ^c Flash chromatography on a silica gel column using ethyl acetate-heptane (2:1-4:1) as eluant.

stirred at 40 °C for 30 min and heated under reflux for 1 h. After evaporation of the solvent, 60 mL of water was added, and the mixture was stirred at room temperature for 3 h. The yellow precipitate was collected, washed with cyclohexane (3 × 6 mL), and dried to give **6b** (2.4 g, 74%) as pale yellow crystals: ¹H NMR (DMSO-*d*₆) δ 13.19 (1H, s, NH-1), 7.73 (1H, s, H-6), 2.56 (2H, q, J = 7.5 Hz, CH_2CH_3), 1.16 (3H, t, J = 7.5 Hz, CH_2CH_3).

3-Nitro-4-(phenylthio)pyridin-2(1H)-ones 7a-f, 3-Nitro-5-methyl-4-[(3',5'-dimethylphenyl)amino]pyridin-2(1H)-one (9), 3-Nitro-4-(arylthio)pyridin-2(1H)-ones 10ah, and 5-Ethyl-6-methyl-3-carbethoxy-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one (16) (Table 6). Preparation of 5-Methyl-3-nitro-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one (7a): Example of the General Method. A mixture of the compound **6a**¹⁰ (1.88 g, 10.0 mmol) in 20 mL of ethanol and 2 mL of triethylamine was stirred until homogeneity. 3,5-Dimethylthiophenol (1.39 g, 10.1 mmol) was added dropwise. After 1 h under stirring at room temperature, the precipitate was filtered off and washed with cyclohexane (20 mL). The product 7a was obtained (2.66 g, 92%) as a yellow solid: mp 235 °C; ¹H NMR (DMSO- d_6) δ 12.27 (1H, s, NH-1), 7.63 (1H, s, H-6), 7.01 (1H, s, H-4'), 6.96 (2H, s, H-2', 6') 2.27 (6H, s, CH₃-3',5'), 1.89 (3H, s, CH₃-5). Anal. $(C_{14}H_{14}N_2O_3S \cdot 0.25H_2O) C, H, N, S.$

3-Amino-4-(phenylthio)pyridin-2(1H)-ones 8a-c,e,f and 3-Amino-5-methyl-4-(benzoxazol-2-ylthio)pyridin-2(1H)one (11) (Table 7). Preparation of 3-Amino-5-methyl-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one (8a): Example of the General Method. To a suspension of 7a (2.50 g, 8.6 mmol) in ethyl acetate (150 mL) was added tin(II) chloride dihydrate (9.75 g, 43.0 mmol). The mixture was heated under reflux under argon for 1 h. After cooling at 0 °C, adding ice water (110 mL), and basifing with a saturated solution of sodium carbonate, the precipitate was eliminated by filtration and washed with water. The filtrate was separated and extracted with ethyl acetate. The combined organic layers were washed with brine $(3 \times 120 \text{ mL})$, dried over magnesium sulfate, and evaporated. The residue was purified by column chromatography using dichloromethane-ethanol (9:1) as eluant giving the product **8a** (2.02 g, 87%) as a pale yellow solid: mp 208 °C; ¹H NMR (DMSO-d₆) δ 11.46 (1H, s, NH-1), 6.82 (1H, s, H-4'), 6.72 (2H, s, H-2',6'), 6.62 (1H, s, H-6), 5.46 (2H, s, NH₂-3), 2.22 (6H, s, CH₃-3',5'), 1.97 (3H, s, CH₃-5). Anal. (C₁₄H₁₆N₂OS) C, H, N, S.

3-Formamido-5-methyl-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one (12a). To a solution of the amine 8a (0.10 g, 0.4 mmol) in ethyl formate (previously distilled on calcium hydride) (8 mL) was added formic acid (2 mL). The mixture was heated under reflux for 12 h. After evaporation of the volatile materials, the residue was washed twice with ethanol and once with ethyl acetate. It was purified by column chromatography using dichloromethane-ethanol (95:5) and pure ethyl acetate as eluants giving 12a (0.06 g, 58%) as a white powder: mp 221-222 °C; ¹H NMR (DMSO-d₆) δ 11.96 (1H, s, NH-1), 8.28 (1H, s, CHO), 7.23 (1H, s, H-6), 6.88 (1H, s, H-4'), 6.78 (2H, s, H-2',6'), 2.23 (6H, s, CH₃-3',5'), 1.85 (3H, s, CH₃-5). Anal. (C₁₅H₁₆N₂O₂S) C, H, N, S.

3-Amido-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1*H*)ones 12b-e,g (Table 8). Method A: 3-Acetamido-5-methyl-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1*H*)-one (12b). A solution of the amine 8a (0.10 g, 0.4 mmol) and acetic anhydride (0.05 mL, 0.39 mmol) in acetic acid (20 mL) was heated to reflux for 1.5 h. After evaporation of the solvents, 10 mL of water was added, and the mixture was neutralized at 0 °C with an aqueous diluted solution of ammonia. After filtration, the residue was washed with cyclohexane (2 × 5 mL). The product 12b was obtained (0.10 g, 86%) as a beige solid: mp 138 °C; ¹H NMR (DMSO- d_6) δ 11.84 (1H, s, NH-1), 9.41 (1H, s, NH-3), 7.20 (1H, s, H-6), 6.87 (1H, s, H-4'), 6.81

Table 8. 3-Amido-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-ones 12b-e,g: Experimental Conditions and Physical Data

no.	reagents and solvents	T (°C) (time, h)	yield (%)	purification technique	mp (°C)	formula	anal.
1 2b	acetic anhydride, acetic acid (method A)	reflux (1.5)	86	cyclohexane washings	138	$C_{16}H_{18}N_2O_2S\cdot H_2O$	C, H, N, S
1 2c	propionyl chloride, NEt ₃ , CH ₂ Cl ₂ (method B)	20 (5)	90	chromatographya	186-188	$C_{17}H_{20}N_2O_2S{\cdot}1.25H_2O$	C, H, N, S
1 2d	heptanoic anhydride, toluene (method A)	100 (1.5)	50	diethyl ether washings, recrystallization in ethyl acetate	212-213	$C_{21}H_{28}N_2O_2S$	C, H, N, S
1 2e	phenylacetyl chloride, NEt ₃ , CH ₂ Cl ₂ (method B)	20 (2)	56	chromatography ^b	200-202	$C_{22}H_{22}N_2O_2S$	C, H, N
1 2g	acetic anhydride, acetic acid (method A)	reflux (5.5)	74	cyclohexane washings	238-239	$C_{18}H_{22}N_2O_2S\cdot 0.45H_2O$	C, H, N, S

^a Flash chromatography on a silica gel column using dichloromethane-ethanol (94:6) and ethyl acetate as eluants. ^b Flash chromatography on a silica gel column using dichloromethane-ethanol (95:5) as eluant.

 $(2H,\,s,\,H\text{-}2',6'),\,2.22\,(6H,\,s,\,CH_3\text{-}3',5'),\,1.99\,(3H,\,s,\,CH_3\text{-}5),\,1.81\,(3H,\,s,\,CH_3\text{-}CO).$ Anal. $(C_{16}H_{18}N_2O_2S\text{-}H_2O)$ C, H, N, S.

Method B: 5-Methyl-3-propionamido-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one (12c). To a solution of the amine **8a** (0.10 g, 0.40 mmol) and triethylamine (0.04 mL, 0.38 mmol) in dichloromethane (5 mL) was added freshly distilled propionyl chloride (0.04 mL, 0.41 mmol) at 0 °C (flask was fitted with a CaCl₂ drying tube). The mixture was stirred at room temperature during 5 h. The solvent was evaporated, water was added, and the solid was filtered off. The residue was purified by column chromatography using dichloromethane–ethanol (94:6) and then pure ethyl acetate as eluants giving 12c (0.10 g, 90%) as a white powder: mp 186–188 °C; ¹H NMR (DMSO-d₆) δ 11.86 (1H, s, NH-1), 8.60 (1H, s, NH-3), 7.21 (1H, s, H-6), 6.88 (1H, s, H-4'), 6.80 (2H, s, H-2',6'), 4.04 (2H, q, J = 7 Hz, COCH₂CH₃), 2.22 (6H, s, CH₃-3',5'), 1.82 (3H, s, CH₃-5), 1.20 (3H, t, J = 7 Hz, COCH₂CH₃). Anal. (C₁₇H₂₀N₂O₂S·1.25H₂O) C, H, N, S.

5-Methyl-3-[N-(ethoxycarbonyl)amino]-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one (12f). Triethylamine (0.10 g, 0.50 mmol) was added to a solution of the amine 8a (0.05 g, 0.20 mmol) in ethanol (2 mL). To this mixture, cooled in ice water, was added dropwise freshly distilled ethyl chloroformate (0.65 g, 6.00 mmol), and the mixture was stirred at room temperature for 48 h. After evaporation of the solvent, 5 mL of water was added. After filtration, the red solid was purified by column chromatography using dichloromethaneethanol (98:2) as eluant to give the recovered amine $\mathbf{8a}$ (0.005 g, 10%) and the compound 12f(0.01 g, 26%) as a white solid: mp 208-210 °C; ¹H NMR (DMSO-d₆) δ 11.83 (1H, s, NH-1), 8.60 (1H, s, NH-3), 7.21 (1H, s, H-6), 6.88 (1H, s, H-4'), 6.80 $(2H, s, H-2', 6'), 4.04 (2H, q, J = 7 Hz, OCH_2CH_3), 2.22 (6H, s, d)$ $CH_{3}-3',5')$, 1.82 (3H, s, $CH_{3}-5)$, 1.19 (3H, t, J = 7 Hz, OCH₂CH₃). Anal. C₁₇H₂₀N₂O₃S (C, H, N, S).

Ethyl 2-Ethyl-3-aminocrotonate (13). Ethyl 2-ethylacetoacetate (150 g, 0.95 mol) and ammonium nitrate (84 g, 1.04 mol) were dissolved in dry tetrahydrofuran (1.1 L). The mixture was stirred for 5 days with a blow of ammonia bubbles. The solvent was evaporated at room temperature under reduced pressure, 1 L of water was added, and the mixture was stirred for 30 min further. The colorless residue was filtered off and crystallized from hexane to give the product 13 (107 g, 72%) as colorless crystals: mp 61 °C; ¹H NMR (CDCl₃) δ 4.11 (2H, q, J = 7 Hz, OCH_2CH_3), 2.17 (2H, q, J = 7 Hz, CH_2CH_3), 1.93 (3H, s, CH₃), 1.24 (3H, t, J = 7 Hz, OCH_2CH_3), 0.94 (3H, t, J = 7 Hz, CH_2CH_3). Anal. (C₈H₁₅-NO₂) C, H, N.

4-Hydroxy-5-ethyl-6-methyl-3-carbethoxypyridin-2(1H)one (14). Sodium (48.34 g, 2.10 mol, lump in kerosene) was dissolved slowly in 530 mL of ethanol under nitrogen. The mixture was heated under reflux, and freshly distilled diethyl malonate (335 mL, 2.20 mol) was added dropwise for 30 min. Still under reflux, the aminocrotonate 13 (150 g, 0.96 mol) in 200 mL of ethanol was added dropwise. The mixture was stirred under reflux for 72 h to give a pale yellow suspension which was cooled at room temperature, and the precipitate was filtered off. The solid was dissolved in water, cooled at 0 °C, and acidified to pH 1 with an aqueous solution of hydrochloric acid. The precipitate was filtered off, washed with water, and recrystallized from toluene to give the product 14 (109.6 g, 51%) as white crystals: mp 196–197 °C; ¹H NMR (DMSO- d_6) δ 11.52 (1H, s, NH*-1), 11.32 (1H, s, OH*), 4.34 (2H, q, J = 7 Hz, COOC H_2 CH₃), 2.39 (2H, q, J = 7.5 Hz, CH_2 CH₃), 2.23 (3H, s, CH₃-6), 1.31 (3H, t, J = 7 Hz, COOCH₂CH₃), 1.02 (3H, t, J = 7 Hz, CH₂CH₃). Anal. (C₁₁H₁₅-NO₄) C, H, N.

5-Ethyl-6-methyl-4-[(3',5'-dimethylphenyl)thio]pyridin-2(1H)-one (17). The compound 16 (120 mg, 0.34 mmol) was dissolved in 6 mL of tetrahydrofuran $-H_2O-37\%$ HCl (18:3: The mixture was stirred at 75 °C for 10 days. The 4). tetrahydrofuran was evaporated, and 5 mL of water was added. The mixture was stirred, and the water was eliminated. The residue was crystallized in ethanol (25 mL) giving the product 17 (50 mg, 59%) as colorless paillettes: mp 277-278 °C; ¹H NMR (DMSO- d_6) δ 11.26 (1H, s, NH-1), 7.22 (3H, s, H-2',4',6'), 5.25 (1H, s, H-3), 2.36 (6H, s, CH₃-3',5'), 2.21 (3H, s, CH₃-6), 1.13 (3H, t, J = 7.5 Hz, CH₂CH₃), CH₂CH₃ signal was overlapped by DMSO signal. Anal. (C₁₆H₁₉NOS 0.25H₂O) C, H, N, S. (In ethanol and 5% sodium hydroxide, the starting material was recovered in majority. Traces of compound were isolated and showed by ¹H NMR the loss of the arylthic part.)

Biology. Evaluation of Antiviral Activity of the Compounds. The effects of the compounds on the replication of HIV-1 were evaluated (see Table 1), as previously described, in CEM-SS cells (a cell line of the lymphocytic lineage) acutely infected with HIV-1 LAI.¹⁹ CEM-SS cells were obtained from Peter Nara and Nevirapine resistant HIV-1 (N119) cells bearing a point mutation at RT codon 181 from D. Richman through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.

The production of virus was measured by quantification of the RT activity associated with the virus particles released in the culture supernatant. Briefly, cells were infected with 100 $TCID_{50}$ for 30 min; after virus adsorption, unbound particles were eliminated by two washes, and cells were cultured in the presence of different concentrations of test compounds for 5 days before virus production determination. The 50% inhibitory concentration of virus multiplication (IC_{50}) was derived from the computer-generated median effect plot of the doseeffect data.20 In parallel experiments, cytotoxicity of the molecules for uninfected cells was measured after an incubation of 5 days in their presence using a colorimetric assay (MTT test) based on the capacity of mitochondrial dehydrogenases of living cells to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide into formazan.²¹ The 50% cytotoxic concentration (CC₅₀) is the concentration at which OD_{540} was reduced by one-half and was calculated using the program mentioned above.

Expression and Purification of the Recombinant HIV-1 RT Enzyme. Yeast cells, transformed with the vector pAB24/RT-4 were used to purify the recombinant HIV-1 RT enzyme as described previously.²² The system for the expression of recombinant HIV-2 RT in *Escherichia coli*²³ was a kind gift of Dr. R. Goody. HIV-2 RT was purified as HIV-1 RT.

RT Assays. Incubation was carried out at 37 °C for 10 min in the presence of different template-primers. (a) Poly(C)-oligo(dG): the reaction mixture contained, in a final volume

of 0.05 mL, 50 mM Tris-HCl, pH 8.0, 5 mM MgCl₂, 4 mM dithiothreitol, $0.48 A_{260}$ /mL poly(C)-oligo(dG) (5:1), 1.0μ Ci [³H]dGTP (28 Ci/mmol), 2 µM dGTP, 80 mM KCl, 1 µg of bovine serum albumin, and 20-50 nM RT. (b) Poly(A)-oligo(dT): same conditions as in a, except that $0.48 A_{260}/mL poly(A)$ -oligo-(dT) (5:1), 0.5 μ Ci [³H]dTTP (46 Ci/mmol), and 20 μ M dTTP were used.

Reactions were stopped by the addition of 1 mL of cold 10% trichloroacetic acid plus 0.1 M sodium pyrophosphate. The precipitates were filtered through nitrocellulose membranes, washed with 2% trichloroacetic acid, dried, and counted in a PPO/POPOP/toluene scintillation mixture.

Reverse Transcription. The plasmid pmCG6 containing the nucleotide fragment 1-4005 of HIV-1 (pmal) in psP64, under the control of the bacteriophage T7 promoter was a kind gift from Dr. J. L. Darlix. E. coli HB101(1035)recA⁻ was used for plasmid amplification. After digestion of this clone with HincII and in vitro transcription using T7 RNA polymerase, RNAs were obtained starting at position +50 of the pmal sequence. In vitro transcription and reverse transcription were performed as described in ref 24.

Inhibition Experiments. All compounds were dissolved in dimethyl sulfoxide (DMSO). Controls were made in the presence of the same final concentration of DMSO. IC_{50} is the concentration required to inhibit recombinant HIV-1 RT activity by 50%.

Acknowledgment. The authors would like to thank the French Agency for Research Against AIDS (ANRS) for partial support of this work and for support of Valérie Dollé in the form of a Doctoral Training Grant. This work was also supported by the Association de Recherches contre le Cancer (ARC), the University of Bordeaux II, and the Conseil Régional d'Aquitaine. We also acknowledge Sylvie Schmitd and Sylvie Thirot for their skillful technical assistance.

References

- Goldman, M. E.; O'Brien, J. A.; Ruffing, T. L.; Schleif, W. A.; Sardana, V. V.; Byrnes, V. W.; Condra, J. H.; Hoffman, J. M.; Emini, E. A. A Nonnucleoside Reverse Transcriptase Inhibitor Active on Human Immunodeficiency Virus Type 1 Isolates Resistant to Related Inhibitors . Antimicrob. Agents Chemother. 1993, 37, 947-949.
- (2) Saari, W. S.; Hoffman, J. M.; Wai, J. S.; Fisher, T. E.; Rooney, C. S.; Smith, A. M.; Thomas, C. M.; Goldman, M. E.; O'Brien, J. A.; Numberg, J. H.; Quintero, J. C.; Schleif, W. A.; Emini, E. A.; Stern, A. M.; Anderson, P. S. 2-Pyridinone Derivatives: A New Class of Nonnucleoside, HIV-1-Specific Reverse Transcriptase Inhibitors. J. Med. Chem. 1991, 34, 2922–2925
- (3) Hoffman, J. M.; Wai, J. S.; Thomas, C. M.; Levin, R. B.; O'Brien, J. A.; Goldman, M. E. Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1 Specific Reverse Transcriptase Inhibitors. Phthalimidoalkyl and -alkylamino Analogues. J. Med. Chem. 1992, 35, 3784-3791. (4) Saari, W. S.; Wai, J. S.; Fisher, T. E.; Thomas, C. M.; Hoffman,
- J. M.; Rooney, C. S.; Smith, A. M.; Jones, J. H.; Bamberger, D. L.; Goldman, M. E.; O'Brien, J. A.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Emini, A. E.; Anderson, P. S. Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Re-
- Evaluation of 2-Fyrianone Derivatives as friv-r-specific Reverse Transcriptase Inhibitors. 2. Analogues of 3-Aminopyridin. 2(1H)-one. J. Med. Chem. 1992, 35, 3792-3802.
 Wai, J. S.; Williams, T. M.; Bamberger, D. L.; Fisher, T. E.; Hoffman, J. M.; Hudcosky, R. J.; MacTough, S. C.; Roome, C. S.; Saari, W. S.; Thomas, C. M.; Goldman, M. E.; O'Brien, J. A.; Emini, E. A.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Anderson, P. S. Synthesis and Evaluation of 2-Pyridinone Deviced Transprinter and Evaluation. (5)Derivatives as Specific HIV-1 Reverse Transcriptase Inhibitors. 3. Pyridyl and Phenyl Analogs of 3-Aminopyridin-2(1H)-one. J. Med. Chem. 1**993**, 36, 249–255.
- (6) Hoffman, J. M.; Smith, A. M.; Rooney, C. S.; Fisher, T. E.; Wai, J. S.; Thomas, C. M.; Bamberger, D. L.; Barnes, J. L.; Williams, T. M.; Jones, J. H.; Olson, B. D.; O'Brien, J. A.; Goldman, M. E.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Emini, A. E.; Anderson, P. S. Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors.

4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-

- one and Analogues. J. Med. Chem. 1993, 36, 953-966.
 (7) Saag, M. S.; Emini, A. E.; Laskin, O. L.; Douglas, J.; Lapidus, W. I.; Schleif, W. A.; Whitley, R. J.; Hildebrand, C.; Byrnes, V. W.; Kappes, J. C.; Anderson, K. W.; Massari, F. E.; Shaw, G. M.; The L. 607 661. Weaking Chem. A Short Turn Clinical M.; The L-697,661 Working Group. A Short-Term Clinical Evaluation of L-697,661, A Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase. N. Engl. J. Med. 1993, 329, 1065-1072
- (8) Houpis, I. N.; Molina, A.; Lynch, J.; Reamer, R. A.; Volante, R. P.; Reider, P. J. Condensation of 2-Methylbenzoxazole with Aromatic Aldehydes Bearing Acidic Protons. A Convenient Coupling in the Synthesis of the HIV-Reverse Transcriptase Inhibitor L-696,229. J. Org. Chem. 1993, 58, 3176-3178.
 (9) Nguyen, C. H.; Bisagni, E. A General Route to 5- and 6-Substi-tion of the Synthesis of the Synthesis
- tuted 4-Amino-2-oxo-1,2-dihydropyridines. Synthesis 1984, 765-766.
- (10) Nguyen, C. H.; Bisagni, E.; Lavelle, F.; Bissery, M.-C.; Huel, C. Synthesis and Antitumor Properties of New 4-Methyl-substitutedpyrido[4,3-b]indoles (g-carbolines). Anti-Cancer Drug Des. 1992, , 219-233.
- (11) Eschweiler, W. Ersatz von an Stickstoff gebundenen Wasserstoffatomen durch die Methylgruppe mit Hülfe von Formaldehyd. (Replacement of a nitrogen bounded hydrogen atom by a methyl group arising from formaldehyde.) Chem. Ber. 1905, 38, 880-882.
- (12) Clarke, H. T.; Gillespie, H. B.; Weisshaus, S. Z. The Action of Formaldehyde on Amines and Amino Acids. J. Am. Chem. Soc. 1933, 55, 4571-4587.
- (13) Legraverend, M.; Nguyen, C. H.; Zerial, A.; Bisagni, E. Synthesis and Biological Evaluation of 3-Deazacytidine and 3-Deazauridine Derivatives. Nucleosides Nucleotides 1986, 5 (2), 125-134.
- (14) Baba, M.; De Clercq, E.; Tanaka, H.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Umezu, K.; Nakashima, H.; Mori, S.; Shigeta, S.; Walker, R. T.; Miyasaka, T. Potent and Selective Inhibition of Human Immunodeficiency Virus type 1 (HIV-1) by 5-Ethyl-6-phenylthiouracil Derivatives through their Interaction with the HIV-1 Reverse Transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2356-2360. (15) De Clercq, E. HIV-1 Specific RT Inhibitors: Highly Selective
- Inhibitors of Human Immunodeficiency Virus type 1 that are Specifically Targeted at the Viral Reverse Transcriptase. Med. Res. Rev. 1993, 13, 229-258.
- (16) Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Nitta, I.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Structure-Activity Relationships of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine Analogues: Effect of Substitu-tions at the C-6 Phenyl Ring and at the C-5 Position on Anti-HIV-1 Activity. J. Med. Chem. 1992, 35, 337–345. (17) Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Nitta, I.;
- Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and Antiviral Activity of Deoxy Analogs of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as Potent and Selective Anti-HIV-1 Agents. J. Med. Chem. 1992, 35, 4713 - 4719
- (18) Pan, B.-C.; Chen, Z.-H.; Piras, G.; Dutschman, G. E.; Rowe, E. C.; Cheng, Y.-C.; Chu, S.-H. Synthesis and Anti-HIV-1 Activities of 6-Arylthio and 6-Arylselenoacyclonucleosides. J. Heterocycl. Chem. 1**994**, 31, 177–185.
- (19) Moog, C.; Wick, A.; Le Ber, P.; Kirn, A.; Aubertin, A. M. Bicyclic Imidazo Derivatives, a New Class of Highly Selective Inhibitors for the Human Immunodeficiency Virus type 1. Antiviral Res. 1994, 24, 275–288. (20) Chou, J.; Chou, T.-C. Dose-effect Analysis with Microcomputers
- : Quantitation of ED₅₀, LD₅₀, Synergism, Antagonism, Low-dose Risk, Receptor Binding and Enzyme Kinetics. Computer Software for Apple II Series and IBM-PC and Instruction Manual; Elsevier-Biosoft, Elsevier Science Publishers: Cambridge, U.K., 1985; pp 19-28
- (21) Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival : Application to Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55-63.
- (22) Sallafranque-Andreola, M. L.; Robert, D.; Barr, P. J.; Fournier, M.; Litvak, S.; Sarih-Cottin, L.; Tarrago-Litvak, L. Human Immunodeficiency Virus Reverse Transcriptase Expressed in Transformed Yeast Cells. Eur. J. Biochem. 1989, 184, 367-
- (23) Müller, B.; Restle, T.; Kühnel, H.; Goody, R. S. Expression of the Heterodimeric Form of Human Immunodeficiency Virus type 2 Reverse Transcriptase in E. coli and Characterization of the Enzyme. J. Biol. Chem. 1991, 266, 14709-14713.
 Bordier, B.; Hélène, C.; Barr, P. J.; Litvak, S.; Sarih-Cottin, L. In Vitro Effect on Antisense Oligonucleotides on Human Immu-
- nodeficiency Virus type 1 Reverse Transcription. Nucleic Acids Res. 1992, 20, 5999–6006.

JM9504058